Trypanosoma cruzi genetic diversity was investigated in 25 isolates (vectors and humans) from the semiarid zone of the State of Rio Grande do Norte, Brazil. Molecular markers (3' region of the 24Salpha rRNA; mitochondrial cytochrome oxidase subunit 2 (COII) gene; spliced leader intergenic region (SL-IR) gene; allelic size microsatellite polymorphism) identified 56% TcIII (100% Panstrongyluslutzi; 50% Triatomabrasiliensis); 40% TcII (91.7% humans; 50% T. brasiliensis) and 4% TcI (human). Microsatellite analysis revealed monoclonal and heterozygous patterns on one or more microsatellite loci in 64% of T. cruzi isolates (92.3% triatomines; 33.3% humans) and 36% putative polyclonal populations (66.7% humans; 7.7% triatomines) by loci SCLE10, SCLE11, TcTAT20, TcAAAT6, all belonging to TcII. Identical T. cruzi polyclonal profiles (88.9%) were detected, mostly from humans. The adaptative natural plasticity of TcII and TcIII and their potential for maintaining human infection in T. brasiliensis were confirmed. Intraspecific and phylogenetic T. cruzi diversity in the sylvatic and domestic transmission cycles in this specific region will provide exclusive control strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.actatropica.2010.03.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic changes that allow artemisinin-resistant parasites to tolerate oxidative stress.
Front Parasitol
September 2024
Centro de Cálculo Científico de la Universidad de Los Andes (CeCalCULA), Universidad de Los Andes (ULA), Mérida, Venezuela.
Artemisinin-based treatments (ACTs) are the first therapy currently used to treat malaria produced by . However, in recent years, increasing evidence shows that some strains of are less susceptible to ACT in the Southeast Asian region. A data reanalysis of several omics approaches currently available about parasites of that have some degree of resistance to ACT was carried out.
View Article and Find Full Text PDFUsefulness of polymerase chain reaction tests in Chagas disease studies.
Front Parasitol
February 2024
National Reference Center for Parasitology, Research Institute of the McGill University Center, Montreal, QC, Canada.
The Polymerase Chain Reaction (PCR) test is a highly sensitive, specific, and rapid diagnostic tool for Chagas disease. Chagas disease is caused by the protozoan flagellate and is endemic to the Americas. While conventional serological methods are still used in the diagnosis of Chagas disease, they are being gradually replaced by molecular methods like PCR.
View Article and Find Full Text PDFUnveiling challenges in real-time PCR strategies for detecting treatment failure: observations from clinical trials on chronic Chagas disease.
Front Parasitol
September 2023
Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr Héctor N. Torres (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Chagas disease (CD) caused by Trypanosoma cruzi remains a Neglected Tropical Disease with limited access to diagnosis and treatment, particularly for chronically infected patients. Clinical trials are underway to improve treatment using new drugs or different regimens, and Real-Time PCR is used to assess the parasitological response as a surrogate biomarker. However, PCR-based strategies have limitations due to the complex nature of T.
View Article and Find Full Text PDFParasitemia and antibody response to benznidazole treatment in a cohort of patients with chronic Chagas disease.
Front Parasitol
September 2023
Laboratório de Parasitologia Médica (LIM-46), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Background: Evaluating the effectiveness of Chagas disease treatment poses challenges due to the lack of biomarkers for disease progression and therapeutic response. In this study, we aimed to assess the clearance of Trypanosoma cruzi ( parasites in a group of benznidazole (BNZ)-treated chronic Chagas disease patients using high-sensitivity quantitative PCR (qPCR) and track antibody levels through a semiquantitative chemiluminescent assay.
Methods: A total of 102 seropositive patients with previous PCR-positive results were enrolled in the study.
Laboratory diagnosis of infection: a narrative review.
Front Parasitol
May 2023
Departamento de Investigación, Instituto Nacional de Parasitología (INP) "Dr. Mario Fatala Chaben", Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Ministerio de Salud de la Nación, Buenos Aires, Argentina.
infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants. However, it is estimated that two-thirds of people with Chagas disease currently live in urban areas and that only 10% of them are aware of it. This review summarizes the most important aspects of the diagnosis of human infection by describing the following aspects of clinical laboratory diagnosis: the most widely used tests available in Latin America and those expected to improve access to diagnosis of the affected population with their implementation; the advantages, disadvantages, and sensitivity of the tests in the different phases of infection; and their usefulness in the acute or chronic phases of infection and in the context of immunosuppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!